Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
21 September 2023 - 9:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K/A
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2023
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
16
Tiomkin St.
Tel
Aviv 6578317, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form
20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
EXPLANATORY
NOTE
This
Form 6-K/A (this “Amended Report”) is being filed to amend the Form 6-K filed with the Securities and Exchange Commission
on September 20, 2023 (the “Original Report”). Due to a clerical error, the Original Report was incorrectly submitted with
previously filed content and this Amended Report amends and replaces the Original Report in its entirety to reflect the correct content.
On
September 20, 2023, Galmed Pharmaceuticals Ltd. (the “Company”), held a Special General Meeting of Shareholders (the “Meeting”).
At the Meeting, the Company’s shareholders voted on all of the proposals described in the proxy statement for the Meeting included
as an exhibit to the Company’s report on Form 6-K filed by the Company with the Securities and Exchange Commission on August 9,
2023. The proposals brought before the shareholders at the Meeting were approved by the shareholders of the Company with the requisite
majority in accordance with the Israeli Companies Law, 5759-1999.
This
Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292
and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-254766).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Galmed
Pharmaceuticals Ltd. |
|
|
|
Date:
September 21, 2023 |
By: |
/s/
Allen Baharaff |
|
|
Allen
Baharaff |
|
|
President
and Chief Executive Officer |
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Dec 2024 to Jan 2025
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Jan 2024 to Jan 2025